The First Listed Bio Startup Incubated in Jeonnam Province... Developing Vaccines and More
2020 Stock Price Increase Reached '1,015.3%'
Advanced Manufacturing Platform Established at Hwasun Biopharmaceuticals First Industrial Complex
Pakcell Bio Co., Ltd., which made headlines in the Korean stock market in 2020 by achieving a surge of over 1,000% compared to its initial public offering price, held an opening ceremony for its new headquarters at the Hwasun Biopharmaceuticals First Industrial Complex on December 17, signaling a new leap forward.
As the first listed bio company in the Jeonnam region, Pakcell Bio began in 2010 as an incubated startup at the Jeonnam Bioindustry Foundation. The company has built technological competitiveness through research and development of NK cell-based anti-cancer immunotherapies.
In September 2020, Pakcell Bio became the first homegrown bio company in the Jeonnam region to be listed on KOSDAQ, establishing itself as a leading success story of Jeonnam Province's bioindustry development policy. Notably, at the time, the company achieved a stock price increase of 1,015.3% among newly listed stocks, ranking first overall and drawing significant attention.
Jeonnam Province has continued to implement policies to build full-cycle infrastructure for vaccines and immunotherapy centered on the Hwasun Vaccine Industry Special Zone, as well as to nurture professional talent and support corporate growth.
The opening of Pakcell Bio's new headquarters is highly significant as a symbolic example of the province's policy achievements spreading to the industrial field.
The opening ceremony was attended by Shim Sangwan, Director of the Research and Bioindustry Division of Jeonnam Province, Lee Hobum, Deputy Governor of Hwasun County, Lee Jejung, CEO of Pakcell Bio, Lim Jirak, member of the Jeonnam Provincial Council, as well as officials from related organizations, business and academic representatives, totaling over 100 participants.
The new headquarters of Pakcell Bio was built on a 13,352-square-meter site in the Hwasun Biopharmaceuticals First Industrial Complex, featuring an Advanced Manufacturing Platform (AMP) facility, office space, and meeting rooms, with a total floor area of 2,132 square meters across two above-ground floors.
As a space integrating research and development and management functions, it will serve as a key hub for the research, development, and commercialization of anti-cancer immunotherapies going forward.
Pakcell Bio has demonstrated technological competitiveness in the field of anti-cancer immunotherapy by confirming meaningful therapeutic effects in clinical trials for liver cancer treatments and securing numerous patents related to NK cell manufacturing technology and associated therapeutic methods. Based on these achievements, the company is steadily expanding its potential to enter the global market.
An official from Jeonnam Province's bioindustry policy team stated, "The opening of Pakcell Bio's new headquarters demonstrates that Jeonnam Province is emerging as a key hub for Korea's bioindustry," adding, "We will continue to support the growth of bio companies with global competitiveness."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
